Cost per delivered dose, which is the number that matters posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Nothing here is financial advice and none of it is a route to a transaction.
Answering the question post #32 raises rather than the one it answers.
Independent testing is a real cost and belongs in the comparison. A cheaper supplier tested every lot may cost more in total.
It is one reading of the data and not the only reasonable one.
Collapsed as off-topic by two members at trust level 3 or above
I had written a reply contradicting post #32 and deleted it. Here is what survived.
Insurance tier placement: a compound might be covered but on a higher tier (higher copay). Moving to a lower tier usually requires prior authorization or documented failure of cheaper alternatives.
I have kept the units in throughout, for the obvious reason.
The most useful pricing posts here are the ones that show the arithmetic rather than the conclusion.
Not disagreeing with anyone above, just adding the bit I keep having to look up.
Compute cost per delivered dose at your dose if you want a number you can act on. That requires knowing your dose, vial volume, and whether you are using a vial or a pen.
Adding a source would improve this post and I do not have one to hand.
Nothing here is financial advice and none of it is a route to a transaction.
It is worth stating the boring hypothesis before the interesting one.
Post #42 and I disagree about the size of the effect, not about the direction.
Where somebody posts a comparison, the useful version states the date, the region and what was included.
Reading it back, the second half matters more than the first.
Taking post #42 at face value and following it one step further.
The most useful pricing posts here are the ones that show the arithmetic rather than the conclusion.
This is the sort of thing the wiki should carry and currently does not.
Price variation between pharmacies: identical prescriptions can cost different amounts at different pharmacies because pharmacies negotiate individually with insurers and manufacturers.
I have said this before in a thread nobody could find, so it is worth repeating.
Insurance tier placement: a compound might be covered but on a higher tier (higher copay). Moving to a lower tier usually requires prior authorization or documented failure of cheaper alternatives.
Marking my place. If it changes for me I will come back and say so.
Post #45 describes the usual case. This is about the unusual one.
Nothing here is financial advice and none of it is a route to a transaction.
That is the practical version. The rigorous version is longer and says the same thing.
The most useful pricing posts here are the ones that show the arithmetic rather than the conclusion.
Second this, and I would have said it less carefully.
Where somebody posts a comparison, the useful version states the date, the region and what was included.
Building on post #56 rather than restating it.
Cost per milligram is the only comparison that survives format differences, but even then it needs care. A pen and a vial are not the same product and cannot be compared on price per milligram alone because dead volume, wastage, and number of doses actually obtainable differ.
That is what the documentation says. What happens in practice is usually close.
Post #55 put the caveat in the right place and I want to underline it.
Compute cost per delivered dose at your dose if you want a number you can act on. Everything else is a comparison of packaging.
The reasoning is more useful than the number, which is why I have shown it.
Answering the question post #58 raises rather than the one it answers.
Insurance tier placement: a compound might be covered but on a higher tier (higher copay). Moving to a lower tier usually requires prior authorization or documented failure of cheaper alternatives.
I would be interested in a counterexample if anyone has one.
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Coming back to: Why the cheapest option is often not the cheapest
Why the cheapest option is often not the cheapest — that is the question, and I have not found it answered plainly anywhere I have looked. Reading back through what has been written here about cheapest…
|
+21 | 25 | 55k | 13mo |
|
Revisiting: List price versus negotiated price versus what you pay
Revisiting: List price versus negotiated price versus what you pay — setting out what I have, and where I think it stops being reliable. Working notes on List price versus negotiated price rather than a…
|
+24 | 28 | 50k | 12mo |
|
Price changes over 2025 and 2026, tabulated and dated
Posting this under the heading it deserves: Price changes over 2025 and 2026, tabulated and dated Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…
|
+4 | 8 | 658 | 14mo |
|
Comparing prices across jurisdictions without misleading yourself
Comparing prices across jurisdictions without misleading yourself — setting out what I have, and where I think it stops being reliable. Working notes on comparing prices across jurisdictions rather than a…
|
+78 | 83 | 33k | 1mo |
|
Cost per milligram, computed honestly across formats
Posting this under the heading it deserves: Cost per milligram, computed honestly across formats Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…
|
2 | 47k | 18mo |
Related topics — sharing the tags cost per milligram, data table, compounding
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Gradient steepness and apparent purity: a worked comparison
On the subject in the title: Gradient steepness and apparent purity: a worked comparison Working notes rather than a conclusion. I have spent a fortnight trying to pin gradient steepness and apparent purity…
|
2 | 51k | 22mo | |
|
Coming back to: A community side-effect dataset, with its response rate and biases
Posting this under the heading it deserves: A community side-effect dataset, with its response rate and biases Everything below is what sits behind that. Community side-effect dataset — I have the observation…
|
+96 | 101 | 33k | 2d |
|
Designing a personal experiment that could change your mind
Posting this under the heading it deserves: Designing a personal experiment that could change your mind Everything below is what sits behind that. I was wrong about designing a personal experiment in a thread…
|
+2 | 6 | 695 | 6mo |
|
[2026 update] Area percent versus weight percent: the confusion that causes most arguments
On the subject in the title: Area percent versus weight percent: the confusion that causes most arguments Working notes rather than a conclusion. Proposing that Area percent versus weight percent deserves a…
|
+65 | 70 | 1.1k | 16d |
|
Manufacturer assistance programmes and their eligibility rules
On the subject in the title: Manufacturer assistance programmes and their eligibility rules Working notes rather than a conclusion. I have spent a fortnight trying to pin manufacturer assistance programmes…
|
+37 | 42 | 32k | 11d |